CYTOKINETICS

Corporate Fact Sheet

Company Overview

Cytokinetics, Inc. (NASDAQ: CYTK) is a biopharmaceutical company focused on the discovery and development of novel small molecule drugs that may address areas of significant unmet clinical needs. Our development activities are directed to advancing multiple drug candidates through clinical trials to demonstrate proof-of-concept in humans, specifically by leveraging our expertise in the cytoskeleton and the biology of muscle function. Our research programs have expanded into research and preclinical activities focused on skeletal and smooth muscle. As a result of our innovation and progress, our promising product pipeline consists of seven novel drug candidates.



*** Being developed under a collaboration and option agreement with Amgen.**

Cytokinetics' prior research directed towards the cytoskeleton generated three potential anti-cancer drug candidates, *ispinesib*, SB-743921 and GSK-923295 which are each novel anti-mitotic compounds. *Ispinesib* and SB-743921 are inhibitors of Kinesin Spindle Protein and GSK-923295 is an inhibitor of CENP-E. Cytokinetics is seeking strategic alternatives for the further development of *ispinesib*, SB-743921 and GSK-923295.

Senior Management

Robert I. Blum, *President & Chief Executive Officer*

Sharon A. Barbari, *EVP, Finance, and Chief Financial Officer*

David W. Cragg, *SVP, Human Resources*

Andrew A. Wolff, M.D., F.A.C.C., *SVP, Clinical Research and Development, and Chief Medical Officer*

Quarter Results as of December 31, 2011

Cash: $49M†

Trading Range: $0.89 – $2.17
52 week trading range

Average Daily Volume: 436,004
52 week trading range

† cash, cash equivalents and investments, excluding restricted cash

Analyst Coverage

Ritu Baral, *Canaccord Genuity*

Charles C. Duncan, Ph.D., *JMP Securities*

Brian Klein, M.D., *Lazard & Company*

Mark Monane, M.D., *Needham & Company, LLC*

Michael G. King, Jr., *Rodman & Renshaw*

Joseph Pantginis, Ph.D., *Roth Capital Partners*

Research Innovation ⇔ Robust Clinical Pipeline

Clinical Development And Research Overview

All of our drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton, a complex biological infrastructure that plays a fundamental role within every human cell. Our research activities are focused on muscle biology, where we have developed significant expertise through our work in heart failure. Our most advanced compound, *omecamtiv mecarbil* (formerly CK-1827452), a novel small molecule cardiac muscle myosin activator, is in Phase IIb clinical testing for the potential treatment of heart failure. Our expertise in heart failure has yielded another potential drug candidate, CK-2017357, a fast skeletal muscle troponin activator, which is in Phase II trials and a smooth muscle myosin inhibitor in non-clinical development. Arising from our oncology research are three clinical drug candidates: *ispinesib*, SB-743921 and GSK-923295.

Clinical Development Programs

Cardiac Muscle Contractility Our cardiac muscle contractility program is currently directed towards the discovery and development of small molecule cardiac muscle myosin activators with the goal of developing novel drugs to treat acute and chronic heart failure. Our lead compound from this program, *omecamtiv mecarbil*, is being evaluated in both intravenous and oral formulations with the goal of establishing a new continuum of care for patients in both the in-hospital and outpatient settings. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize *omecamtiv mecarbil* and related compounds, subject to Cytokinetics' specified development and commercialization participation rights.

Smooth Muscle Contractility Our smooth muscle contractility program is focused on the discovery and development of small molecule smooth muscle myosin inhibitors. In January 2009, Cytokinetics announced the selection of a lead drug candidate from this program, which is currently in IND-enabling studies. This compound is a direct inhibitor of smooth muscle myosin, which directly leads to the relaxation of contracted smooth muscle. This potential drug candidate has demonstrated encouraging pharmacological activity in preclinical models as a novel mechanism vasodilator and bronchodilator, suggesting that it may be useful as a potential treatment of diseases such as asthma or chronic obstructive pulmonary disease.

Skeletal Muscle Contractility Cytokinetics' skeletal muscle contractility program is focused on the discovery and development of small molecule skeletal sarcomere activators. Cytokinetics' skeletal sarcomere activators have demonstrated pharmacological activity that may lead to new therapeutic options for diseases associated with aging, muscle wasting, and neuromuscular dysfunction. By directly improving skeletal muscle function, a small molecule activator of the skeletal sarcomere may potentially enhance physical performance and quality of life in aging patients. CK-2017357, the lead potential drug candidate from this program, is being evaluated in: ALS, claudication, and myasthenia gravis.

Oncology Clinical Development Cytokinetics' cancer program is focused on mitotic kinesins, a family of motor proteins essential to cell division. Our prior research generated three potential anti-cancer drug candidates, *ispinesib,* SB-743921 and GSK-923295, which are novel anti-mitotic compounds. *Ispinesib* and SB-743921 are inhibitors of kinesin spindle protein and GSK-923295 is an inhibitor of centromere-associated protein E. Cytokinetics is seeking a partner for these three drug candidates.

Research Activities in Muscle Biology

Cytokinetics' research activities are focused on muscle biology. We are conducting translational research with our existing series of skeletal sarcomere activators to explore the potential applications of this novel approach in preclinical studies. In addition, we have a research program aimed at the discovery and validation of other chemically and pharmacologically distinct mechanisms to activate the skeletal sarcomere. We are continuing to conduct early research activities to develop direct smooth muscle myosin inhibitor compounds for systemic administration for potential use in acute or chronic settings. Our research focus is to differentiate our compounds from existing drugs that act by indirectly causing smooth muscle relaxation, such as commonly used calcium channel blockers. We are particularly interested in potential applications for our compounds where the benefits of currently available treatments are constrained by adverse side effects or limited effectiveness.

CYTOKINETICS

280 East Grand Avenue · South San Francisco, CA 94080 · 650-624-3000 · www.cytokinetics.com